The virion host shutoff (vhs) protein encoded by herpes simplex virus type 1 (HSV-1) destabilizes both viral and host mRNAs. An HSV-1 strain with a mutation in vhs is attenuated in virulence and induces immune responses in mice that are protective against corneal infection with virulent HSV-1, but it has the capacity to establish latency. Similarly, a replication-incompetent HSV-1 strain with a mutation in ICP8 elicits an immune response protective against corneal challenge, but it may be limited in viral antigen production. We hypothesized therefore that inactivation of vhs in an ICP8
Herpes simplex virus type 1 (HSV-1) is a common human pathogen, infecting approximately 80% of individuals by adulthood (49) . The virus typically enters the body at epithelial and mucosal surfaces, where lytic infection of epithelial cells and fibroblasts leads to infection of sensory neurons innervating the mucosa and to the rapid establishment of latent infection in the neuronal cell bodies. In this latent reservoir, HSV infection is maintained for the life of the host. Either initial infection or reactivation can result in serious human disease, including rare but devastating encephalitis and keratitis, which is the second most common cause of nontraumatic corneal blindness (49) . A vaccine to obviate or therapeutically alleviate these HSV-1-mediated diseases is a desirable goal.
Development of an antiviral vaccine requires consideration of both safety and immunogenicity. An effective balance between these can be difficult to achieve, especially when faced with HSV that has a complex and persistent lifestyle. Immunization with live attenuated virus has the potential advantages of generating immune responses to a broad spectrum of viral proteins and induction of type 1 T-cell as well as humoral responses. In the development of prototypic live virus vaccines, several viral proteins that regulate host cell and viral synthetic processes have been manipulated to advantage. During infection, one of the earliest viral activities is that mediated by the virion host shutoff (vhs) protein, a product of the UL41 gene. This viral tegument component exerts its effects immediately upon entry into the cell, prior to viral gene expression (13, 39) . The vhs protein is associated with degradation of both cellular and viral mRNAs (24-26, 36, 39, 43) and endoribonucleolytic activity (9, 52) , and the destabilization of viral messages mediated by vhs has been theorized to promote the switch from transcription of one kinetic class of viral genes to the next (43) . We have previously shown that mice immunized with an HSV-1 strain that is deficient in vhs activity, UL41NHB, are significantly protected against corneal challenge with virulent HSV-1 in a model of HSV-1-induced ocular disease (47) . Replication of challenge virus in the cornea and acute and latent infection of the trigeminal ganglia all are reduced in mice immunized with UL41NHB compared with mice immunized with UV-inactivated virus. Protection against shedding of HSV-1 from the cornea after UVB radiation-induced reactivation can also be achieved by therapeutic immunization of latently infected mice (46) . A second viral gene that has been modified in vaccine approaches is UL29, which encodes ICP8. Numerous viral gene products are expressed by cells infected with ICP8
Ϫ virus, including the major viral glycoproteins gB and gD, but because ICP8 is essential for virus DNA replication (6, 27, 48, 50) , progeny virions are not produced. We have shown that prophylactic immunization of mice with a replication-incompetent HSV-1 strain deficient in ICP8, d301, similarly reduces acute infection of the cornea and trigeminal ganglia and latent infection in the nervous system compared to that in mice immunized with UV-inactivated virus (29) . Immunization with d301 elicits humoral (29) and cytolytic T-cell (3) responses. We have demonstrated that protection against acute infection and disease after corneal challenge is long-lived (30) and is dependent on both HSV-immune antibodies and T cells (31) .
Evidence of safety and immunogenicity in potential vaccine strains must be carefully extrapolated from mice to humans. UL41NHB is profoundly attenuated in mice, showing decreased capacity to replicate when inoculated intracranially or onto the scarified cornea. UL41NHB also establishes latency with reduced frequency and reactivates poorly upon explant of infected trigeminal ganglia (42) . Despite these properties, UL41NHB theoretically retains the potential to cause disease in vaccinated humans because it is replication competent. d301, in contrast, is avirulent even in immunocompromised mice (L. A. Morrison and D. Knipe, unpublished observation). In addition, there is no amplification of viral DNA in the vaccinated host or latent infection in the nervous system (8) . The adequacy of the immune response to a replication-incompetent virus remains a concern, however, because production of immunogenic viral proteins is limited to cells initially infected by the vaccine virions. We hypothesized that a vaccine strain defective in both vhs and ICP8 functions would be as immunogenic as vhs Ϫ virus, with improved immunogenicity and protective capacity over an ICP8 Ϫ virus. A vhs Ϫ /ICP8
Ϫ double mutant HSV-1 strain therefore was constructed and compared, using a mouse model of corneal infection with HSV-1, to vhs Ϫ , replication-incompetent and ICP8 Ϫ , replication-competent viruses for immunogenicity and protection against disease and latent and fatal infection.
MATERIALS AND METHODS

Cells and viruses.
Vero and S2 cells were cultured as previously described (15) . S2 cells stably express the ICP8 (single-stranded DNA-binding protein; product of UL29) of HSV-1 (15 (19) were propagated on Vero cells. Cell lysate stocks of all viruses were prepared by infection of S2 or Vero monolayers as previously described (30) and were used for in vitro assays. Partially purified, cell-free virus stocks were prepared as previously described (30) and were used for immunization studies. Uninfected control lysates and supernatants were prepared in the same manner as infected stocks. Titers of virus stocks were determined by standard plaque assay (22) .
Generation of ⌬41⌬29. vhs/ICP8-deficient virus was constructed by insertional inactivation of the UL29 gene in the vhs mutant virus UL41NHB. Briefly, 1 g of pICP8-LacZ plasmid DNA, containing the UL29 open reading frame (ORF) disrupted by a human cytomegalovirus (HCMV) IE:␤-galactosidase (␤-Gal cassette (7), and 1 g of infectious UL41NHB DNA were cotransfected into S2 cells using Lipofectamine (Gibco BRL). Cultures were collected when they reached 100% cytopathic effect (CPE), then frozen, thawed, sonicated, and serially diluted onto S2 cell monolayers. Blue plaques were picked 72 h after the addition of agarose overlay supplemented with X-Gal (160 g/ml). Isolates were plaque purified three times and analyzed for replication deficiency by comparing plaque formation on the complementing S2 cell line and noncomplementing Vero cells.
Southern blot analysis. To confirm disruption of UL29 and UL41, 1 g of viral DNA from each plaque isolate was digested with HpaI or EcoRV (New England Biolabs), electrophoresed on a 1% agarose gel, and transferred to nitrocellulose membranes for Southern hybridization. A 2-kb PstI/EcoRI fragment from pUL41 (42) was used to probe for the presence of an HpaI restriction site in the UL41 locus. A 2-kb NotI fragment of p8BS (15) was used to probe for the presence of a lacZ insertion in the UL29 locus. Southern blotting was performed as described elsewhere (38, 40) , using the Alk Phos Direct Southern hybridization kit (Amersham Life Science), according to the manufacturer's directions. Images were obtained using a Storm PhosphorImager (Molecular Dynamics).
Northern blot analysis and mRNA degradation assay. Total cytoplasmic RNA was prepared from monolayer cultures of infected or mock-infected Vero cells as described previously (42) . Monolayer cultures of 5 ϫ 10 5 to 5 ϫ 10 6 cells were mock infected or infected at a multiplicity of infection (MOI) of 20 with KOS, KOS1.1, HD-2, ⌬41⌬29, or BGS41 in the presence of actinomycin D (10 g/ml). Mock-infected plates received Vero cell lysate only. Cytoplasmic RNAs were harvested at 8 h postinfection and analyzed for mRNA degradation by Northern blot analysis probing for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (14, 42) . Filters were first probed for GAPDH, stripped, and then reprobed for the 28S ribosomal subunit as a loading control. Phosphorimages were scanned on a Storm 860 PhosphorImager (Molecular Dynamics) and quantified. The level of GAPDH for mock-infected cells was set at 100% and compared with the 28S-normalized GAPDH values of virus-infected cells.
Multistep growth assay. S2 cell monolayers in 12-well plates were infected with KOS, KOS1.1, BGS41, HD-2, or ⌬41⌬29 virus at approximately 100 PFU/ well and were incubated at 37°C for 0 to 36 h. At each time point, monolayers were scraped, collected, and frozen at Ϫ80°C. Titers were determined by standard plaque assay.
Animals and inoculations. Female BALB/c mice (6 weeks of age), purchased from the National Cancer Institute, were housed in accordance with Public Health Service (1) and institutional guidelines and were rested for 1 week before use. Mice were immunized subcutaneously (s.c.) in each rear flank with 20 l of partially purified virus suspended in low-endotoxin normal saline. Twenty-four days after immunization, mice were anesthetized with pentobarbital sodium (Nembutal) and challenged with HSV-1 mP in a 5-l volume after bilateral scarification of the corneas (5). Doses of immunizing and challenge viruses are indicated in the text.
ELISA. Blood was collected from the tail veins of immunized mice 5 days prior to challenge. HSV-1-specific immunoglobulin G (IgG) titers in sera were determined by enzyme-linked immunosorbent assay (ELISA) as described previously (28) . Briefly, Immulon-2 96-well microtiter plates (Dynex Technologies) were incubated with lectin-purified HSV-1 KOS glycoprotein (37) for 48 h at 4°C and blocked with phosphate-buffered saline (PBS) containing 5% goat serum (GIBCO) for 2 h at 20°C. Serial twofold dilutions of sera in PBS plus 0.1% Tween 20 were added in duplicate to plates and were incubated for 2 h at 20°C. Wells were washed and incubated for 2 h with biotinylated goat anti-mouse IgG (Caltag), followed by 30-min incubation with streptavidin-HRP (Zymed). Wells were developed by the addition of 0.4 mg of o-phenylenediamine (OPD; Sigma)/ml plus 0.05% hydrogen peroxide and read at 490 and 630 nm with an EL340 microplate reader (BIOTEK). HSV-specific serum IgG concentrations were calculated based on comparison to a standard curve generated from serum for which the HSV-specific IgG concentration is known. HSV-specific IgG concentration in the standard serum had been previously determined by comparison to dilutions of purified IgG captured on an anti-kappa-coated plate (28) . Geometric mean titers plus or minus the standard error of the mean (SEM) were calculated for each immunizing dose.
Acute replication. Acute replication of mP in the cornea was assayed on days 0 through 4 postchallenge as previously described (30) .
Clinical disease. Blepharitis and weight change were monitored as clinical signs of HSV-induced disease. Blepharitis was scored in a masked manner to avoid bias. Disease was estimated on a scale of 0 to 4: 0, no apparent disease; 1, slight swelling and erythema of the eyelid; 2, moderate swelling and crusty exudate; 3, periocular lesions, severe swelling, and depilation; and 4, severe lesions, swelling, and depilation. Weight change was assessed daily from days 0 through 8. The mean weight change plus or minus the standard error of the mean compared with initial body weight was calculated daily for each group.
Latent and lethal infections. Thirty days after challenge, surviving mice were sacrificed, and trigeminal ganglia were explanted to Vero cell monolayers as previously described (31) . Reactivation was scored by the presence of CPE at 10 days postexplant. Monolayers showing no CPE after 10 days were scraped and homogenized using a minibead beater (BioSpec Products). Homogenized samples were incubated with fresh Vero monolayers and observed for 3 days for CPE. The proportion of mice in each group surviving challenge infection was recorded at 30 days postchallenge.
Statistics. The difference in means for antibody titers and weight loss on individual days was determined by the Student t test (BGS41 or ⌬41⌬29 versus HD-2). The severity of blepharitis was compared between groups using the nonparametric Kruskal-Wallis test; the parametric general linear models test yielded similar results. Differences in keratitis incidence, reactivation frequencies, and survival were compared by chi-square analysis of 2 by 2 contingency tables.
RESULTS
Construction and in vitro characterization of a vhs
؊
/ICP8
؊ HSV-1 mutant. To test the hypothesis that ablation of the UL41 gene (vhs) in a replication-incompetent HSV-1 strain would enhance the immune response to vaccination, a virus was constructed that contained disrupted UL41 and UL29 genes. Infectious DNA from the replication-competent, vhs Ϫ strain, UL41NHB, was cotransfected with a plasmid, p8BS, containing a portion of the UL29 gene in which a 2-kb NotI fragment was replaced with a cytomegalovirus IE1 promoter: ␤-galactosidase cassette. This insertion disrupts the open reading frame of the essential UL29 gene, as previously reported (15) . Recombinant plaques that developed on an ICP8-complementing cell line were screened by blue-white selection in the presence of X-Gal. Isolates that exhibited blue staining and replication incompetence were subjected to Southern blot analysis to verify disruption of UL29 and UL41. A probe span-ning a portion of the UL41 locus confirmed the presence of a stop codon containing a unique HpaI restriction site (42; data not shown). EcoRV digestion of the wild-type genome yields a 14.8-kb fragment that encompasses the UL29 locus. Insertion of lacZ into the UL29 locus would increase its size by 3.1 kb but would also introduce an additional EcoRV site in the middle of lacZ. Thus, a probe spanning the lacZ insertion point in the UL29 locus would yield 2 bands of 4.6 and 13.3 kb and confirm disruption of UL29. One isolate that exhibited the appropriate banding pattern by Southern analysis (Fig. 1) was designated ⌬41⌬29.
Multistep growth assays were performed in ICP8-complementing S2 cells to compare in vitro replication of ⌬41⌬29 with wild-type and single-mutant viruses. Titers of vhs Ϫ /ICP8 Ϫ ⌬41⌬29 were not significantly different from those of wild-type KOS1.1, ICP8-defective HD-2, or vhs-defective BGS41 over several rounds of replication in culture (Fig. 2) , although slightly higher titers of wild-type virus were consistently observed after 36 h of culture. Growth kinetics of ⌬41⌬29 were also similar to those of wild-type KOS and to UL41NHB and d301, the HSV-1 strains used in the original immunization studies with single-mutant viruses (29, 47 ; data not shown). Single-step growth assays revealed identical kinetics among wild-type, single-mutant, and double-mutant viruses over a 24-h period (data not shown). To verify ablation of vhs activity in ⌬41⌬29, Northern blot analysis of GAPDH mRNA levels in cells infected with wild-type, ICP8 Ϫ , vhs Ϫ , or vhs Ϫ /ICP8 Ϫ virus was performed. Vero cells were infected with virus at an MOI of 20 in the presence of actinomycin D, and at 8 h postinfection, total RNA was extracted and electrophoresed. Wild-type KOS-and KOS1.1-infected cells showed decreased levels of GAPDH message compared to mock-infected cells (Fig. 3) . Cells infected with replication-incompetent HD-2 virus also showed a decrease in GAPDH message, indicating that ICP8 Ϫ virus has wild-type vhs activity. Cells infected with BGS41 or ⌬41⌬29 exhibited no decrease in GAPDH message compared to the mock-infected control, indicating that vhs function is compromised in these viruses. The vhs deletion, rather than the effect of actinomycin D, is responsible for the observed decrease in vhs activity because a similar decrease in activity was detected in S2 cell cultures infected with ⌬41⌬29 in the absence of the drug (data not shown).
Immunization studies. To compare protective efficacy of a vhs-defective, replication-incompetent HSV-1 with that of either vhs-defective or replication-incompetent single mutants, a dose-response experiment was performed. To control for expression of ␤-Gal by ⌬41⌬29, the lacZ ϩ viruses HD-2 and BGS41 were used in this in vivo comparison. Groups of six BALB/c mice were immunized s.c. with control supernatant or with 4 ϫ 10 5 PFU, 1 ϫ 10 5 PFU, or 2.5 ϫ 10 4 PFU of either HD-2, BGS41, or ⌬41⌬29 viruses. Twenty-four days after immunization, mice underwent bilateral corneal challenge with 8 ϫ 10 5 PFU of virulent HSV-1 mP. Seven parameters were monitored in this experiment: prechallenge IgG titers, acute replication of challenge virus at the site of infection, weight change, blepharitis, keratitis, survival, and reactivation of virus from trigeminal ganglia of mice that survived infection. Altogether, four experiments were performed that yielded remarkably consistent results.
Prechallenge serum IgG. It has been previously shown that immunization with either ICP8 Ϫ or vhs Ϫ mutant viruses can elicit a humoral immune response (29, 47) . As one measure of immune induction, we determined whether inactivation of vhs in a replication-incompetent virus alters serum antibody titer. Sera were collected 19 days after immunization, and HSVspecific IgG titers in individual serum samples were analyzed by ELISA. When immunized with the 4 ϫ 10 5 PFU dose of virus, all mice showed similar high levels of HSV-specific IgG (Fig. 4) . Groups immunized with the 10 5 -PFU dose of BGS41 and ⌬41⌬29 exhibited almost 1 log 10 (six-to eightfold) higher than those immunized IgG titer with HD-2 (P Յ 0.002). At the 
ϫ 10
4 PFU dose, titers of mice immunized with BGS41 or ⌬41⌬29 again were similar, and they exceeded the titers observed with HD-2, although, due to variability within the HD-2 titers, this difference was not statistically significant. Overall, the titer induced by HD-2 immunization dropped more rapidly with decreasing dose.
Acute replication. Mice were challenged by application of virulent HSV-1 mP to the scarified corneas, and acute replication of challenge virus was analyzed from days 0 through 4 postchallenge. Immunization with any of the viruses prior to challenge significantly reduced acute replication in the eye compared to control vaccination, and the magnitude of the protection was dose dependent (Fig. 5) . In this and subsequent experiments, however, there was no significant difference between the immunizing viruses in their capacities to reduce acute replication.
Body weight change. During the progression of HSV-1 infection, mice lose weight in a manner consistent with the severity of disease. Thus, weight change can be used as a sensitive indicator of overall health. Over the first 8 days postchallenge, mice immunized with control supernatant quickly lost weight (Fig. 6 ). For each immunizing virus, weight loss postchallenge was inversely proportional to the immunizing dose. At the 4 ϫ 10 5 -PFU immunizing dose, all three viruses inhibited weight loss to a similar degree (Fig. 6A) . At the 10 5 PFU dose, HD-2-immunized mice consistently lost an average of 1 g more than BGS41-or ⌬41⌬29-immunized mice (Fig. 6B) . The difference between HD-2 and ⌬41⌬29 and BGS41 was statistically significant from day 3 and beyond (P ϭ 0.01 to 0.05). At later times during infection, HD-2-immunized mice regained weight, but they did not recover to prechallenge weight. Mice immunized with 2.5 ϫ 10 4 PFU showed an even greater disparity between the BGS41-and ⌬41⌬29-immunized groups and the HD-2-immunized group (Fig. 6C) . BGS41-and ⌬41⌬29-immunized groups consistently exhibited similar weight losses, which were more moderate than that seen with the HD-2 group. By day 8, BGS41-and ⌬41⌬29-immunized mice had, in fact, begun to regain weight. The greater weight loss in HD-2-immunized mice was statistically significant beginning at 5 days postchallenge (P Յ 0.01).
Blepharitis. Disease of the eyelid resulting from virulent HSV-1 infection was scored in a masked fashion from days 0 to 8 postinfection. Only occasional mild blepharitis was observed in groups immunized with 4 ϫ 10 5 PFU of any of the viruses, compared to those given control immunizations (Fig. 7A) , and ⌬41⌬29-immunized mice differed from HD-2-immunized mice only at 3 days postchallenge (P Ͻ 0.013). Greater differences were observed, however, when lower doses of immunizing virus were used. At 10 5 PFU, mice immunized with HD-2 exhibited significantly more severe blepharitis from days 3 to 6, compared to those given BGS41 and ⌬41⌬29 (P Ͻ 0.001 to 0.015), which subsided after day 6 (Fig. 7B) . Differential protection from blepharitis was most pronounced at the 2.5 ϫ 10 4 PFU dose, where BGS41-and ⌬41⌬29-immunized mice showed minimal disease, but HD-2-immunized mice had significantly elevated scores from days 4 through 8 (P Ͻ 0.002 to 0.013) (Fig. 7C) . Experimental groups in which mortality was significant could not be used for assessment of keratitis and reactivation frequencies. Thus, several experiments were performed using immunizing doses of 1 ϫ 10 5 PFU to address keratitis and latent infection and 2 ϫ 10 4 PFU to assess survival. Data from three such experiments were pooled for these analyses.
Keratitis and latent infection. Keratitis was scored in masked fashion at 9 days postchallenge. A higher frequency of severe keratitis, defined as scores of 3ϩ or 4ϩ, was consistently observed in HD-2-immunized mice compared to mice immunized with ⌬41⌬29 or BGS41 ( Table 1 ). The incidence of severe keratitis among mice immunized with ⌬41⌬29 was not statistically different from that of mice immunized with BGS41.
Latent infection of the trigeminal ganglia was assessed by explant cocultivation assay in groups in which all or nearly all mice survived the challenge infection. Results pooled from two experiments showed that mice immunized with BGS41 and ⌬41⌬29 had a lower frequency of reactivation than did those immunized with HD-2 ( Table 1) . In a third experiment using a lower challenge dose, reactivation from ganglia of ⌬41⌬29-and HD-2-immunized mice was again significantly different (P Ͻ 0.026), but in this case reactivation frequency of BGS41-immunized mice was intermediate (data not shown).
Lethal infection. Table 2 shows mortality results pooled from three separate experiments in which lethal infection was observed. Significantly fewer mice succumbed to infection in groups immunized with BGS41 or ⌬41⌬29 than in those immunized with HD-2. Thus, the trend toward a reduction in lethality and in reactivatable virus in the trigeminal ganglia is consistent with the overall picture of stronger immune protection afforded by immunization with ⌬41⌬29. (47) and replication-incompetent (29, 30) viruses and viruses that undergo a single round of replication in the host (11) had suggested the utility of live attenuated viruses as an effective approach to prophylactic vaccination against HSV. Postexposure vaccination of mice with vhs Ϫ virus has also been shown to have therapeutic benefit (46) . Because vhs is a virion component and is expressed as a ␥1 gene product, it would be present upon infection and would also be synthesized de novo in cells infected with ICP8-deficient vaccine viruses. This knowledge led us to hypothesize that a vhs Ϫ /ICP8 Ϫ double-mutant virus might retain the distinct advantages of both the vhs Ϫ and ICP8 Ϫ single-mutant strains: increased immunogenicity and safety, respectively. We have shown that an HSV-1 strain lacking both vhs and ICP8 functions, ⌬41⌬29, has immunogenicity and protective capacity similar to that of a replication-competent, vhs Ϫ single-mutant virus. In addition, ⌬41⌬29 promotes better protection from local and systemic signs of disease and from latent and lethal infection than an equivalent dose of the replication-incompetent ICP8
Ϫ virus. It is interesting that less blepharitis occurred after challenge of mice immunized with BGS41 or ⌬41⌬29 compared with HD-2. The observations that nude mice develop more severe blepharitis than normal mice (2) and that depletion of both CD4 ϩ and CD8 ϩ T cells before challenge enhances development of periocular skin lesions (16) suggest that T cells are important in clearance of virus from periocular skin and in limiting disease. Such a role for T cells in clearance from dermal lesions has been reported (32) (33) (34) 51) . It follows then that mice in which a stronger or more competent immune response has been induced would be able to more effectively prevent development of blepharitis (41) . It is interesting that a corresponding decrease in virus shed into tear film was not observed in our experiments, although the titers of virus in the periocular skin were not determined. In contrast to blepharitis, keratitis is mediated by an immunopathologic infiltration of the cornea in primary immune responses to virus infection (35) or to a neoantigen revealed by virus infection (53) . This raises two possibilities: that some types of immune responses may be protective, while others are pathogenic, and that a more protective type of response is induced by vhs Ϫ viruses. Alternatively, HD-2 may not sufficiently prime mice to mount a secondary, protective immune response in the eye and eyelid. The slower kinetics of blepharitis development in HD-2-and control supernatant-immunized mice supports this possibility.
Differences in protection from latent infection, as assessed by frequency of reactivation of ganglia explanted from mice at 4 weeks postchallenge, were observed in experimental groups in which immunizing doses were Ն10 5 but not among survivors that had been immunized with lower doses of virus. Protection from latent infection may be the most difficult demand placed on a prophylactic vaccine (30) because virus enters the nervous system quickly and latency can be established in mouse trigeminal ganglia in the absence of replication or clinical signs of disease (20, 23) . It is possible that the capacity of the doublemutant virus to protect mice against latent infection as compared with that of the ICP8 Ϫ single mutant would be differentially enhanced if greater immunizing doses or lower challenge doses were given. We currently are examining this possibility.
␤-Gal is expressed in different locations and under control of different promoters in the viruses used in this study. ␤-Gal is known to be immunogenic when encoded by the virus (4), and thus it could have influenced the strength of the immune response to HSV in a bystander fashion if expressed at different levels in cells infected by the three mutant viruses. ␤-Galspecific antibody responses in serum from mice immunized with the double-or single-mutant viruses were uniformly low (data not shown), suggesting therefore that virus-expressed ␤-Gal had little impact on virus-specific immune responses.
With the exception of the vhs protein, ⌬41⌬29 has the genetic potential to express the same spectrum of immunogenic proteins as ICP8-deficient HD-2. The equivalent immunogenicity of ⌬41⌬29 and BGS41 must be a function of increased viral-protein production due to loss of vhs activity, and/or it is a function of decreased interference with host antigen presentation functions such as major histocompatibility complex (MHC) class I molecule synthesis and cell surface expression. Viruses in which the vhs gene is deleted or inactivated show prolonged viral message stability, resulting in an accumulation of mRNAs of all three kinetic classes (24, 36, 39, 43) and a corresponding increase in the amount of IE, E, and L viral proteins (24, 39) . We found clear evidence for a lack of vhs activity in the ⌬41⌬29 double mutant, in contrast to ICP8 Ϫ mutants, by Northern blot analysis of cellular GAPDH message. Thus, an increase in stability of both cellular and viral mRNAs could be expected in cells infected with ⌬41⌬29 rather than ICP8 Ϫ virus. We have not, however, obtained clear-cut evidence of increased viral protein expression, and analyses of specific viral proteins from different kinetic classes are in progress to clarify this issue.
vhs of HSV-1 and HSV-2 has been shown to down-regulate synthesis of MHC class I heavy chain molecules in human fibroblasts (18, 44) , resulting in decreased recognition and lysis of the infected cells by MHC class I-restricted cytotoxic T lymphocytes (44) . We have extended these findings by demonstrating that HSV-1-infected mouse fibroblasts exhibit lower cell surface expression of class I molecules than cells infected with an HSV-1 strain lacking vhs (L. Thebeau and L. A. Morrison, unpublished observations). Notably, vhs-mediated loss of class I molecules from the cell surface is independent of ICP47, which has been shown to interfere transporter associated with antigen processing (TAP) function in human cells 
/ICP8
Ϫ virus may contribute to its increased immunogenicity when compared to replication-incompetent virus with wild-type vhs activity. Because the vhs activity of HSV-2 is stronger than that of HSV-1 (10, 12) , it will be interesting to assess the immunogenicity of an HSV-2 vhs Ϫ /ICP8 Ϫ mutant compared with an ICP8 Ϫ HSV-2 strain.
Whether maintenance of MHC class I expression results in enhanced HSV-specific cytotoxic T-lymphocyte activity in mice immunized with ⌬41⌬29 is not yet known. We have, however, demonstrated that antibody responses are increased in mice immunized with ⌬41⌬29 as compared to HD-2. By inference, this suggests that helper T-cell responses may be enhanced in mice immunized with vhs-deficient viruses. The higher antibody titer correlates with better protective efficacy, but it may be responsible for only certain aspects of the enhanced protection. We have previously shown that serum antibody affects development of encephalitis but does not alter acute replication in the cornea when passively transferred at physiologic levels prior to challenge (31) . Regardless of the mechanism by which the immunogenicity of replication-incompetent ⌬41⌬29 is enhanced to levels near that of replication-competent, vhs Ϫ virus, our data argue that the inactivation of vhs is an important feature for the future engineering of a safe and efficacious vaccine strain.
